{"id":"https://genegraph.clinicalgenome.org/r/1daa519b-0d81-4109-84fe-99cf86587a35v1.1","type":"EvidenceStrengthAssertion","dc:description":"*EMG1* (EMG1 N1-specific pseudouridine methyltransferase) is located on chromosome 12 at position 12p13.31. The protein is key in processing of pre-18S rRNA and small ribosomal subunit formation. *EMG1* was first reported in relation to autosomal recessive Bowen-Conradi Syndrome (BCS) in 2009 (Armistead et al., PMID: 19463982). This condition is characterized by facial anomalies such as micrognathia and prominent nose, joint contractures, congenital microcephaly, rocker bottom foot/clubbed foot, and digit anomalies including camptodactyly. BCS is often lethal within the first year of life due to complications linked to motor issues and poor growth. \n\nOne variant (missense, p.(Asp86Gly)) that has been reported in 39 probands from 29 nuclear families in the highly consanguineous Hutteritte population, and in one publication, is included in this curation (PMID: 19463982). A founder effect is suspected. The mechanism of pathogenicity appears to be gain-of-function. This gene-disease relationship is also supported by experimental evidence including functional alteration, expression-level evidence, and mouse models (Liu & Thiele, 2001, PMID: 11694595; Eschrich et al., 2001, PMID: 11935223; Wu et al., 2010, PMID: 20858271; Armistead et al., 2015, PMID: 25708872). Functional alteration evidence shows that rRNA processing is inhibited when *EMG1* is mutated. The protein localized to the nucleus in a yeast cell analysis. Mouse models show that the mutants exhibited early embryonic lethality, abnormal expression of early cell lineage markers, increased apoptosis, and neural tube defects.The impact of other variants in *EMG1* is unknown; given the single position (p.Asp86Gly) involved to date, other variants would need very careful consideration. \n\nIn summary, the classification of this gene-disease relationship was upgraded from moderate to strong based on the strength of evidence, particularly the evidence from the mouse models and the restrictions in scoring founder variants through the framework. This classification was approved by the ClinGen Syndromic Disorders GCEP on the meeting date May 16th, 2025 (SOP Version 11).\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/1daa519b-0d81-4109-84fe-99cf86587a35","GCISnapshot":"https://genegraph.clinicalgenome.org/r/c60e824f-3e52-4e94-9181-d9f7290f6023","calculatedEvidenceStrength":"Moderate","changes":[{"id":"cg:newEvidence"},{"id":"cg:otherTextChange"},{"id":"cg:classificationChange"},{"id":"cg:summaryChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/c60e824f-3e52-4e94-9181-d9f7290f6023_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10060","date":"2025-05-16T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/c60e824f-3e52-4e94-9181-d9f7290f6023_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10060","date":"2025-06-30T16:21:49.391Z","role":"Publisher"}],"curationReasonDescription":"The classification of this gene was upgraded from moderate to strong due to the strength of evidence and the restrictions in scoring founder variants through the framework. ","curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c60e824f-3e52-4e94-9181-d9f7290f6023_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c60e824f-3e52-4e94-9181-d9f7290f6023_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/95583c0f-29f9-4000-bdee-c9699f27d32c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/42b3cb49-c0f2-4938-9e4f-8cc2b8273336","type":"Finding","dc:description":"PLY12 (MYC-EMG1) cell analysis showed localization of EMG1 to the nucleus. Antibody staining was done in this analysis ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11694595","rdfs:label":"PLY12 yeast cell expression analysis ","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c60e824f-3e52-4e94-9181-d9f7290f6023_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f246626a-bad3-4f03-b3cd-6c05a1c26c8d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/82d9c1b0-54d7-44ea-a569-c0d65c6f744f","type":"FunctionalAlteration","dc:description":"In the wild-type, rRNA processing was finished by 2 minutes of chase. This was evident in how the primary 35S rRNA transcript was rapidly processed into 20S and 27S intermediates and subsequently the mature 18S and 25S species were created. This process was slower in the mutant cells.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11694595","rdfs:label":"PLY21 yeast cell analysis "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1cff4129-5ed1-4903-afa0-62db22f5ab21","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/459d8f3c-c4c8-4401-8b3b-65753ea3d9a3","type":"FunctionalAlteration","dc:description":"Results showed that lack of EMG1 function as a result of temperature change occurs along with a reduction in polysomes. For the temperature sensitive cells, there was significantly more isolated 60S ribosomal subunit, indicating a lack of subunit balance due to less 40S ribosomal subunits. This indicates that EMG1 is necessary for 40S ribosomal subunit biogenesis. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11935223","rdfs:label":"Polysome analysis & ribosomal subunit quantification "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c60e824f-3e52-4e94-9181-d9f7290f6023_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f0ec5374-0ecd-4534-a995-3e8926cbfe63","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cec01d09-cd79-4188-8ee9-817fd117eaec","type":"Finding","dc:description":"The embryonic lethality and abnormal apoptosis in mutant mice reflect the features of neonatal death, small for gestational age, and microcephaly seen in humans. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25708872","rdfs:label":"Mouse model #2","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1135d538-3c58-41ec-9602-102bd5284339","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5a6b9b6b-0819-4648-9084-7ea1d38675c2","type":"Finding","dc:description":"The abnormal nucleogenesis and increased apoptosis in mice are consistent with the microcephaly and growth delay seen in humans. Also, the embryonic lethality reflects the neonatal death seen in humans. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20858271","rdfs:label":"Mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5.5},{"id":"https://genegraph.clinicalgenome.org/r/c60e824f-3e52-4e94-9181-d9f7290f6023_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c60e824f-3e52-4e94-9181-d9f7290f6023_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0066200e-e6fd-4383-81ce-a6f6c827079e_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19463982","rdfs:label":"Hutterite population; 39 probands from 29 sects","estimatedLodScore":22.88,"family":{"id":"https://genegraph.clinicalgenome.org/r/0066200e-e6fd-4383-81ce-a6f6c827079e","type":"Family","rdfs:label":"Hutterite population; 39 probands from 29 sects","member":{"id":"https://genegraph.clinicalgenome.org/r/81e27871-4408-474b-a4bc-27a2cbe40eaa","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19463982","rdfs:label":"Proband A, p.Asp86Gly","ageType":"AgeAtOnset","ageUnit":"Days","allele":{"id":"https://genegraph.clinicalgenome.org/r/4dce6f00-9f06-4e40-a448-916f1101a39d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006331.8(EMG1):c.257A>G (p.Asp86Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA114613"}},"detectionMethod":"mapping and sequencing of coding exons of EMG1 done ","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"developmental delay was severe, joint restrictions were minor ","phenotypes":["obo:HP_0001838","obo:HP_0000252","obo:HP_0000448","obo:HP_0000347","obo:HP_0001263","obo:HP_0001518","obo:HP_0001387"],"secondTestingMethod":"Genotyping","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/42d465f4-3f07-4704-a8a0-c8bc9e7d2e83_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19463982","allele":{"id":"https://genegraph.clinicalgenome.org/r/4dce6f00-9f06-4e40-a448-916f1101a39d"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"most consistent features are micrognathia, prominent nose, hip contractures, and rocker bottom feet (present in 100 %, 97 %, 86 %, 84 %, and 82 % of probands, respectively); other symptoms include camptodactyly (74 % of probands), congenital microcephaly (64 %), clinodactyly (64 %), small for gestational age (57 %), undescended testes (57 %), club feet (53 %), breech presentation (52 %); less common features are congenital heart defect (21 %), cleft lip/palate (13 %), hypospadia (4 %), & seizures (13 %)","phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":39,"phenotypes":["obo:HP_0001623","obo:HP_0001518","obo:HP_0000047","obo:HP_0000028","obo:HP_0001838","obo:HP_0000175","obo:HP_0034671","obo:HP_0410030","obo:HP_0003273","obo:HP_0001762","obo:HP_0011451","obo:HP_0000448","obo:HP_0012385","obo:HP_0030084","obo:HP_0000347","obo:HP_0001627"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/81e27871-4408-474b-a4bc-27a2cbe40eaa"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/81e27871-4408-474b-a4bc-27a2cbe40eaa_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/81e27871-4408-474b-a4bc-27a2cbe40eaa"},{"id":"https://genegraph.clinicalgenome.org/r/42d465f4-3f07-4704-a8a0-c8bc9e7d2e83","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/42d465f4-3f07-4704-a8a0-c8bc9e7d2e83_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/42d465f4-3f07-4704-a8a0-c8bc9e7d2e83_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"mRNA levels are the same between control and affected patient fibroblasts. However,  Immunoblot analysis shows that concentrations of EMG1 protein were significantly decreased in affected patient fibroblasts compared to control fibroblasts. \nAlso, wild-type and mutant EMG1 underwent fusion to the GAL4-activation or DNA-binding domain and were evaluated against one another via co-expression in the yeast two-hybrid analysis. Binding affinity was quantified using Î²-galactosidase activity. The human and yeast EMG1 proteins have strong interaction in the yeast two-hybrid system, indicating that EMG1 is a dimer or multimer. Interactivity between the mutant subunits was 10X greater than the wild-type subunits. Also interaction between the wild-type subunit and the mutant subunit was greater than that of the wild-type subunits with each other. \n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":4}],"evidenceStrength":"Strong","sequence":10719,"specifiedBy":"GeneValidityCriteria11","strengthScore":9.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/nVYvWvErBec","type":"GeneValidityProposition","disease":"obo:MONDO_0008879","gene":"hgnc:16912","modeOfInheritance":"obo:HP_0000007"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_c60e824f-3e52-4e94-9181-d9f7290f6023-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}